|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Breast Cancer Market Report shows that the degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape. Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.
Other Key Points in Report:
-The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
-A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
-The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
-Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
-Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
-Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170048/buying
Table of Content: An Overview
2 Executive Summary 4
2.1 Exceptionally Large and Innovative Pipeline 4
2.2 Alignment of First-in-Class Molecular Target with Disease Causation 4
2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 4
3 The Case for Innovation in the Breast Cancer Market 5
3.1 Growing Opportunities for Biologic Products 5
3.2 Diversification of Molecular Targets 5
3.3 Innovative First-in-Class Product Developments Remain Attractive 5
3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 5
3.5 Sustained Innovation 6
3.6 Report Guidance 6
4 Clinical and Commercial Landscape 8
4.1 Disease Overview 8
4.2 Epidemiology 8
4.3 Disease Symptoms 9
4.4 Etiology 9
4.4.1 Age and Gender 9
4.4.2 Genetic Makeup 9
4.4.3 Environmental 10
4.5 Pathophysiology 10
4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 10
4.5.2 Tumor Metabolic Shift 11
4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 12
4.5.4 Cancer Stem Cells 13
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170048/discount
4.6 Diagnosis 13
4.7 Prognosis and Disease Staging 14
4.7.1 Classification 15
4.8 Introduction to Breast Cancer Treatments 16
4.9 Surgery and Radiation Therapy 17
4.10 Overview of Marketed Products for Breast Cancer 17
4.10.1 Chemotherapy 18
4.10.2 Hormonal Therapies 19
4.10.3 Targeted Therapies 19
4.11 Treatment Algorithm 21
4.12 Current Unmet Need in Breast Cancer Market 23
5 Assessment of Pipeline Product Innovation 25
5.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target 25
5.2 First-in-Class Pipeline Programs 29
6 Signaling Network, Disease Causation and Innovation Alignment 36
6.1 The Complexity of Signaling Networks in Oncology 36
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 37
6.3 First-in-Class Target Matrix Assessment 37
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170048/buy/6995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
